Collegium Pharmaceutical (COLL) vs Ironwood Pharmaceuticals (IRWD)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Ironwood Pharmaceuticals (IRWD) has outperformed Collegium Pharmaceutical (COLL) over the past year, gaining 146.7% versus a loss of 34.3%. Over five years, COLL leads with a +4.5% price change compared with -72.5% for IRWD. Collegium Pharmaceutical is the larger company by market cap ($713.9 million vs $619.6 million), about 1.2 times the size.
On valuation, Ironwood Pharmaceuticals trades at a lower forward P/E (2.5x vs 3.3x for Collegium Pharmaceutical).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | COLL | IRWD |
|---|---|---|
| Share price | $21.93 | $3.75 |
| Market cap | $713.94M | $619.65M |
| 1-day change | +0.23% | +3.31% |
| YTD return | -52.63% | +11.28% |
| 1-year return | -34.32% | +146.71% |
| 5-year return | +4.53% | -72.55% |
| P/E ratio (TTM) | 17.27 | 4.69 |
| Forward P/E | 3.30 | 2.50 |
| EPS (TTM) | $1.27 | $0.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $50.79 | $5.78 |
| 52-week low | $21.43 | $1.41 |
| Distance from 52-week high | -56.82% | -35.12% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +123.44% | +62.67% |
| Average volume | 747.73K | 2.03M |
| Shares outstanding | 32.56M | 165.24M |
| Employees | 423 | 100 |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Drug Manufacturers - Specialty & Generic |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IRWD has outperformed COLL by 181.0 percentage points over the past year.
- Collegium Pharmaceutical trades at a higher earnings multiple (17.3x vs 4.7x trailing P/E).
About Collegium Pharmaceutical
COLL stock →Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Healthcare · Drug Manufacturers - Specialty & Generic · 423 employees
About Ironwood Pharmaceuticals
IRWD stock →Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation, as well as for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names.
Healthcare · Drug Manufacturers - Specialty & Generic · 100 employees
COLL vs IRWD FAQ
Which is bigger, Collegium Pharmaceutical or Ironwood Pharmaceuticals?
Collegium Pharmaceutical (COLL) is larger, with a market capitalization of $713.94M compared with $619.65M for Ironwood Pharmaceuticals (IRWD).
Which stock has performed better over the past year, COLL or IRWD?
IRWD returned +146.71% over the past 12 months, compared with -34.32% for COLL (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, COLL or IRWD?
IRWD has the lower trailing P/E at 4.7, versus 17.3 for COLL. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Collegium Pharmaceutical and Ironwood Pharmaceuticals in the same industry?
Yes. Both are classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector.